Related Experiment Video
Updated: Jun 15, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
American heart association, 2009 scientific sessions
Insights
The ARBITER 6-HALTS study investigated lipid treatment strategies. Findings on lipid effects on cardiovascular disease and cancer were presented at the American Heart Association 2009 Scientific Sessions.
Area of Science:
- Cardiology
- Clinical Trials
- Lipid Metabolism
Background:
- The American Heart Association (AHA) 2009 Scientific Sessions convened in Orlando, Florida.
- Key research presented included late-breaking clinical trials and sessions on cardiovascular disease and cancer.
Purpose of the Study:
- To provide an overview of significant findings from the AHA 2009 Scientific Sessions.
- To highlight the ARBITER 6-HALTS lipid treatment strategy study.
- To cover trials on angiotensin-receptor blockers in heart failure and lipid effects on cardiovascular disease and cancer.
Main Methods:
- Review of late-breaking clinical trial presentations.
- Analysis of sessions examining lipid effects on cardiovascular disease and cancer.
- Coverage of a clinical trial on angiotensin-receptor blockers for heart failure.
Main Results:
- The ARBITER 6-HALTS lipid treatment strategy study generated significant attention and controversy.
- Clinical trials explored the impact of lipids on cardiovascular disease and cancer.
- Angiotensin-receptor blockers were evaluated in the context of heart failure.
Conclusions:
- The AHA 2009 Scientific Sessions showcased critical advancements in cardiovascular research.
- Lipid management remains a key focus in cardiovascular disease prevention and treatment.
- Further research is needed to understand the complex relationship between lipids, cardiovascular health, and cancer.
Abstract:
The American Heart Association (AHA) 2009 Scientific Sessions hosted nearly 22,000 cardiologists, other health professionals, and industry exhibitors in Orlando, Florida, from November 14 to 18, 2009. This overview covers the late-breaking clinical trial presentation of ARBITER 6-HALTS, a lipid treatment strategy study that attracted more attention and controversy than others; a clinical trial of angiotensin-receptor blockers in heart failure; and two other sessions that examined the effects of lipids on both cardiovascular disease and cancer.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Cardiomyopathy V: Interprofessional Care

